| Hopital-Sainte-Justine Patent applications |
| Patent application number | Title | Published |
|---|
| 20120009600 | METHOD OF DIAGNOSING ADOLESCENT IDIOPATHIC SCOLIOSIS - A method for diagnosing an increased risk for developing adolescent idiopathic scoliosis (AIS) in a human subject, comprising detecting the presence or absence of at least one impairment in melatonin-signaling pathway in a cell sample of the subject in the presence and in the absence of a known melatonin-signaling pathway agonist, wherein the cell sample is selected from the group consisting of blood cell sample, osteoblast cell sample, osteoclast cell sample and myoblast cell sample, and wherein the presence of the at least one impairment in the melatonin-signaling pathway indicates that the subject possesses an increased risk for developing AIS. | 01-12-2012 |
| 20110256582 | METHOD OF CLASSIFYING HUMAN SUBJECTS HAVING ADOLESCENT IDIOPATHIC SCOLIOSIS (AIS) AND METHOD FOR SCREENING FOR A COMPOUND USEFUL IN THE TREATMENT OF AIS AND RELATED SYNDROMES CAUSING SPINAL DEFORMITIES - A method of classifying a human subject having adolescent idiopathic scoliosis (AIS) comprising: providing a cell sample isolated from the subject; detecting an impairment in melatonin-signaling pathway in the sample in the presence and in the absence of a known melatonin-signaling pathway agonist, whereby the results of the detecting step enables the classification of the subject having AIS in one AIS subgroup; and a method of screening for a compound useful in the treatment of a disease characterized by a dysfunctional melatonin-signaling pathway, said method comprising the steps of contacting a candidate compound with at least one cell expressing at least one melatonin-signaling pathway impairment, wherein the candidate compound is selected if said melatonin-signaling pathway impairment is reduced in the presence of the candidate compound as compared to that in the absence thereof. | 10-20-2011 |
| 20100029692 | METHODS OF OPTIMIZING DRUG THERAPEUTIC EFFICACY FOR TREATMENT OF IMMUNE-MEDIATED GASTROINTESTINAL DISORDERS - The present invention provides a method of optimizing therapeutic efficacy and reducing toxicity associated with 6-mercaptopurine drug treatment of an immune-mediated gastrointestinal disorder such as inflammatory bowel disease. The method of the invention includes the step of determining the level of one or more 6-mercaptopurine metabolites in the patient having an immune-mediated gastrointestinal disorder. | 02-04-2010 |
